Physician profile
Anthony C Chang
NPI 1417951062
$4,133.74
in general payments reported to CMS, 2019-2025
21 companies · $438 in 2025
The $438 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,076 · 2020: $191 · 2021: $32.69 · 2022: $148 · 2023: $102 · 2024: $146 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,364.38 | 2019-2020 | |
| Abbott Laboratories | $328.56 | 2019-2025 | Aveir |
| Pfizer INC. | $322.51 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $223.55 | 2019-2025 | |
| Boston Scientific Corporation | $150.47 | 2019-2025 | Cds - Mct/Cem Monitoring |
| Janssen Pharmaceuticals, INC | $125.62 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $100.25 | 2020-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $84.03 | 2019-2024 | Brilinta |
| Merck Sharp & Dohme LLC | $82.43 | 2025 | Verquvo, Lagevrio |
| Amgen INC. | $66.74 | 2019-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $41.14 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.76 | 2019 | |
| Esperion Therapeutics, INC. | $33.98 | 2024-2025 | Nexletol |
| Abiomed | $32.07 | 2025 | |
| Kestra Medical Technology Services, INC. | $24.54 | 2025 | Assure Wcd |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.78 | 2025 | |
| Heartflow, INC. | $21.03 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $20.53 | 2023 | Arcalyst |
| Recor Medical INC | $20.40 | 2025 | Paradise Ultrasound Renal Denervation System |
| Edwards Lifesciences Corporation | $17.73 | 2019 | |
| Cvrx, INC. | $16.24 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.